Filing summary
Entity mismatch: The request identifies Decoy Therapeutics Inc., but the supplied Form 10-Q is for Salarius Pharmaceuticals, Inc. This summary reflects the filing provided, not Decoy Therapeutics.
Business context and reporting period
This unaudited 10-Q covers the quarter and six months ended June 30, 2021. Salarius is a clinical-stage biopharmaceutical company developing seclidemstat (SP-2577), an LSD1 inhibitor, for cancers including Ewing sarcoma and other FET-rearranged sarcomas. It has no products approved for sale and no product-sales revenue; reported revenue is from a CPRIT research grant.
Financial results and liquidity
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Grant revenue | $0.57 million | $1.24 million | $1.84 million | $2.38 million |
| Research and development expense | $2.10 million | $1.44 million | $3.84 million | $3.09 million |
| General and administrative expense | $1.59 million | $1.70 million | $2.92 million | $3.56 million |
| Net loss | $3.07 million | $1.78 million | $4.93 million | $3.87 million |
| Basic and diluted loss per share | $0.07 | $0.13 | $0.13 | $0.33 |
At June 30, 2021, cash and cash equivalents were $33.1 million, CPRIT grants receivable was $4.8 million, working capital was $36.8 million, and total assets were $47.4 million. Total liabilities were $1.55 million; the $0.48 million note payable at year-end 2020 had been repaid. Six-month operating cash outflow was $5.90 million, versus $6.18 million in 2020. Financing provided $27.86 million, mainly from equity offerings and warrant exercises, and cash increased by $21.96 million. The company reported an accumulated deficit of $24.4 million. Profit margins are not meaningful given the company’s operating losses and grant-based revenue.
Material changes and unusual items
- Q2 net loss widened by $1.29 million year over year; six-month net loss increased by $1.06 million. Lower grant revenue and higher R&D spending were major factors.
- Q2 R&D expense rose 45% year over year, attributed to higher personnel, clinical-trial enrollment costs, and laboratory activity. Six-month G&A expense fell 18%, principally due to lower legal and personnel costs, including nonrecurring 2020 severance.
- CPRIT grant revenue declined because the company had reached the maximum eligible spending reimbursable under the grant. The filing reports $4.8 million receivable, and the grant term was extended to November 30, 2021; the company says allowable grant funds have been expended.
- Equity issuance and warrant exercises materially increased cash but also increased share count: 44.8 million shares were issued and outstanding at June 30, versus 23.8 million issued at December 31, 2020. The company raised about $27.0 million net through 2021 stock sales and received about $1.5 million from warrant exercises during the first half.
Outlook, risks, and contingencies
- Management said available cash plus collection of the CPRIT receivable should fund anticipated requirements through completion of current clinical trials in 2022 and beyond, but substantial additional capital will be needed. No assurance is given that financing will be available on acceptable terms.
- The Ewing sarcoma Phase 1/2 trial’s expansion is to study seclidemstat with topotecan and cyclophosphamide; expansion also includes single-agent treatment in myxoid liposarcoma and other FET-rearranged sarcomas. An investigator-initiated Phase 1/2 trial combines seclidemstat with azacitidine for MDS/CMML; preliminary data were expected by mid-2022.
- The Advanced Solid Tumor trial completed dose escalation in June 2021 and closed to enrollment; the company reported encouraging preliminary activity in FET-rearranged sarcoma patients and was assessing potential larger solid-tumor indications. These are company-reported preliminary findings, not established efficacy.
- COVID-19 had caused minimal disruption as of the filing, but could delay trials, disrupt suppliers, increase costs, or impair access to financing. The company also highlighted dependence on CPRIT and the risk of grant repayment in certain termination or default circumstances.
- Nasdaq listing compliance is a risk: the filing notes a July 29, 2021 closing share price of $0.85 and describes potential delisting risk if the bid price remains below $1.00 for the specified period.
- After quarter-end, the company registered an additional $25.0 million of potential ATM stock sales on July 2, 2021. On July 12, the SBA authorized forgiveness of its $0.2 million PPP loan.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is Salarius Pharmaceuticals, Inc., not Decoy Therapeutics Inc.
- Check collection of the $4.8 million CPRIT receivable, grant status and any remaining conditions, given that allowable funds were exhausted.
- Track cash burn, clinical-trial spending, financing needs, and potential dilution from ATM sales and other equity issuance.
- Review subsequent clinical data and trial timing against management’s stated expectations; distinguish preliminary results from confirmed clinical benefit.
- Monitor Nasdaq bid-price compliance and any changes in COVID-19-related trial, manufacturing, or financing risks.